Free Trial

Universe Pharmaceuticals (UPC) Competitors

$2.33
-0.26 (-10.04%)
(As of 05/20/2024 ET)

UPC vs. GRTX, CMMB, MTEM, ATHE, NCNA, ADXN, AEZS, GHSI, MBRX, and GRAY

Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Galera Therapeutics (GRTX), Chemomab Therapeutics (CMMB), Molecular Templates (MTEM), Alterity Therapeutics (ATHE), NuCana (NCNA), Addex Therapeutics (ADXN), Aeterna Zentaris (AEZS), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), and Graybug Vision (GRAY). These companies are all part of the "pharmaceutical preparations" industry.

Universe Pharmaceuticals vs.

Universe Pharmaceuticals (NYSE:UPC) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Galera Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Galera Therapeutics N/A N/A -138.81%

Galera Therapeutics received 50 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.

CompanyUnderperformOutperform
Universe PharmaceuticalsN/AN/A
Galera TherapeuticsOutperform Votes
50
54.35%
Underperform Votes
42
45.65%

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Universe Pharmaceuticals has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.

Universe Pharmaceuticals has higher revenue and earnings than Galera Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$32.31M0.28-$6.16MN/AN/A
Galera TherapeuticsN/AN/A-$59.08M-$0.99-0.19

In the previous week, Universe Pharmaceuticals and Universe Pharmaceuticals both had 1 articles in the media. Galera Therapeutics' average media sentiment score of 0.54 beat Universe Pharmaceuticals' score of 0.00 indicating that Galera Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Universe Pharmaceuticals Neutral
Galera Therapeutics Positive

Summary

Universe Pharmaceuticals and Galera Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPC vs. The Competition

MetricUniverse PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$9.20M$6.62B$4.93B$17.99B
Dividend YieldN/A2.72%44.82%3.43%
P/E RatioN/A10.00117.6222.99
Price / Sales0.28246.442,468.4510.86
Price / CashN/A20.5032.2315.96
Price / Book0.236.005.025.05
Net Income-$6.16M$136.27M$101.60M$973.44M
7 Day Performance8.78%7.14%5.41%2.89%
1 Month Performance22.71%10.47%9.46%7.79%
1 Year Performance-36.81%-1.49%9.72%25.27%

Universe Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRTX
Galera Therapeutics
0 of 5 stars
$0.18
flat
N/A-93.6%$9.57MN/A-0.127Gap Down
CMMB
Chemomab Therapeutics
3.0533 of 5 stars
$0.88
+8.6%
$5.67
+543.9%
-53.1%$9.72MN/A-0.5520Gap Up
MTEM
Molecular Templates
2.5491 of 5 stars
$1.49
+6.4%
N/A-79.0%$9.80M$57.31M-0.9662Earnings Report
Gap Down
ATHE
Alterity Therapeutics
2.3546 of 5 stars
$2.10
+1.4%
$7.00
+233.3%
-31.0%$9.81M$3.37M0.0011Positive News
Gap Down
NCNA
NuCana
3.2759 of 5 stars
$3.78
+1.3%
$125.00
+3,206.9%
-80.8%$9.86MN/A-0.2425
ADXN
Addex Therapeutics
0 of 5 stars
$9.45
+1.3%
N/A-39.6%$10.02M$1.83M-0.5223Gap Up
AEZS
Aeterna Zentaris
2.2708 of 5 stars
$8.40
flat
$60.00
+614.3%
-28.0%$10.16M$4.50M-0.6211Positive News
Gap Down
High Trading Volume
GHSI
Guardion Health Sciences
0 of 5 stars
$8.55
+3.9%
N/A+28.9%$10.56M$12.25M77.699
MBRX
Moleculin Biotech
2.0583 of 5 stars
$4.85
+3.9%
$35.00
+621.6%
-46.0%$10.80MN/A0.0018
GRAY
Graybug Vision
0 of 5 stars
$5.20
-7.1%
N/A+81.7%$8.17MN/A-3.0127Gap Down
High Trading Volume

Related Companies and Tools

This page (NYSE:UPC) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners